Novel Systemic Anticancer Therapy and Healthcare Utilization at the End of Life: A Retrospective Cohort Study
Novel SACT use at the end of life is high and is strongly associated with HCRU. Future studies should explore the impact of advance care planning and palliative care referrals on SACT use.
Authors
- Alejandra Ruiz Buenrostro
- Stéphanie Lheureux (ORCID: https://orcid.org/0000-0003-4405-5890)
- Breffni Hannon (ORCID: https://orcid.org/0000-0002-0881-555X)
- Camilla Zimmermann (ORCID: https://orcid.org/0000-0003-4889-0244)
- Kirsten Wentlandt (ORCID: https://orcid.org/0000-0002-1873-7794)
- Suman Dhanju
- John Kuruvilla (ORCID: https://orcid.org/0000-0002-6117-320X)
- Mohamed Yousef (ORCID: https://orcid.org/0000-0002-7489-7397)
- Rebecca Bagnarol
- Vikas Garg
- Katrina Heuniken
- Katrina Sajewicz
Institutions
- University Health Network (CA)
- University of Toronto (CA)
- Princess Margaret Cancer Centre (CA)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/cam4.70450
- Primary Topic
- Palliative Care and End-of-Life Issues
- Type
- article
- Field-Weighted Citation Impact
- 0.00